The self-service integration enables users to analyze tumor microenvironments at single-cell resolution using routine H&E slides.
PathAI has announced that PathExplore is now available on the AISight Image Management System, with early access open to select academic medical centers. The integration allows researchers to explore tumor-immune landscapes at scale while leveraging PathAI’s AI-powered digital pathology platform.
PathExplore delivers a structured panel of human interpretable features from H&E whole-slide images. Powered by PathAI’s foundation model PLUTO, the tool spatially characterizes the tumor microenvironment at single-cell resolution and supports cohort-scale analysis across tumor types.
The platform provides visual overlays of tumor segmentation and immune cell prediction, enabling quantification of key tumor features such as density of tumor infiltrating lymphocytes. A bulk analysis workflow allows teams to process large H&E image cohorts with integrated feature extraction for downstream research.
“PathExplore represents a true innovation in the biomarker discovery space, enabling H&E tissue, cellular and spatial data to be structured at scale in a way that is not possible via manual methods,” says professor Charles Swanton, PhD, chair in personalised medicine at University College London, in a release. “The fact that this structured histology data can then be mined for novel correlations to molecular status, drug response, and prognosis has tremendous potential for translational and precision medicine.”
Cloud-Native Platform Integration
The integration brings PathExplore capabilities to AISight’s cloud-native digital pathology platform, which many academic medical centers already use for case and image management. AISight integrates with major laboratory information systems, enabling rapid activation of PathExplore without requiring new on-premises infrastructure.
Teams can review PathExplore outputs within their existing AISight workflows, helping maintain study alignment across sites and supporting reproducible cohort-level analyses.
“Launching PathExplore on AISight meets academic researchers where they already work,” says Nick Brown, chief growth officer of PathAI, in a release. “Early access sites can quantify the immune microenvironment from routine H&E at single-cell resolution, collaborate in one workspace, and scale analyses across cohorts to speed translational discovery and refine biomarker selection strategies.”
Both PathExplore and AISight are designated for research use only and are not intended for use in diagnostic procedures.
ID 408578847 © Alena Butusava | Dreamstime.com
